What You Should Know:
– Cerner announced a strategic investment in Elligo
Health Research, a leading research organization that enables clinical trials
with nationwide community-based health care practices.
– Cerner plans to expand the data and tools available in
the Cerner Learning Health Network to offer additional clinical trial resources
to community and rural hospitals and physician practices.
– Financial terms of strategic investment were not disclosed.
Cerner Corporation today announced an undisclosed strategic investment in Elligo Health Research, a leading integrated research organization that enables clinical trials with nationwide community-based health care practices. As part of the strategic investment, Cerner will enter into a commercial agreement to expand the data and tools available in the Cerner Learning Health Network to offer additional clinical trial resources to community and rural hospitals and physician practices.
Single Platform to Accelerate Clinical Research
Founded by John Potthoff, Ph.D., and Chad Moore in 2016, Elligo
Health Research Since 2016, Elligo Health Research, founded by John Potthoff,
Ph.D., and Chad Moore, has accelerated the development of new pharmaceutical,
biotechnology, medical device, and diagnostic products using its novel clinical
technology and its Goes Direct® approach. As one of the largest health networks
for clinical research, Elligo works to bring research as a care option to as
many participants as possible by offering innovative, patient-centric solutions
within the practices of trusted physicians.
Collaboration Will Accelerate Clinical Research
Health systems face significant obstacles such as patient recruitment, costs, and access to clinical trial resources. Today, for example, the drug development process takes more than 17 years and costs approximately $2.5B. Cerner and Elligo will focus on helping reduce those obstacles health systems face to make clinical trials become more of a reality – no matter the size, location, or academic standing.
Additionally, most clinical trials are executed in large,
urban areas with homogenous trial populations, which offer insights that may
not be broadly applicable to all patients in need of the therapies. Clinical trial
resources can offer funded research opportunities for health care organizations
as well as access to trial therapies for patients who need it most, including
those in minority populations and rural communities. This could result in
outcomes that are more representative of diverse populations and a potential
increase in drug safety through post-market surveillance capabilities.
This collaboration is expected to help accelerate clinical
research timeframes, make clinical trials more broadly and easily accessible
and reduce the costs associated with bringing a therapy to market. In addition,
Cerner representatives will also join Elligo’s board of directors.
“At the beginning of the year, we launched a bold push with our provider clients to change the pace and cost of clinical trials. Today, 51 health systems are part of our Learning Health Network,” said Donald Trigg, president, Cerner. “Elligo shares our passion for making clinical trial opportunities accessible to every provider and patient. Our collaboration will accelerate that shared mission in the quarters ahead.”